Hong Kong Stock Alert | CLOVER BIO-B (02197) Surges Over 21% Following Announcement of Phase I Clinical Trial Launch for Respiratory Combination Vaccine Candidates

Stock News10-02

CLOVER BIO-B (02197) surged over 21%, rising 21.15% to HK$2.75 with trading volume of HK$42.2186 million at the time of reporting. On the news front, in June this year, Clover Biopharmaceuticals announced that its respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) (Pre-F trimeric subunit vaccine antigens), developed based on the company's proprietary Trimer-Tag (protein trimerization) vaccine development platform, have completed enrollment of the first batch of subjects and officially launched Phase I clinical trials. Clover Biopharmaceuticals' Chief Executive Officer and Executive Director Liang Guo previously pointed out that while currently approved recombinant protein RSV vaccines are safe and effective, there remain key unmet clinical needs globally—including the inability to prevent and reduce the respiratory disease burden caused by viruses with similar RSV structures such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163204562?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 11:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163204562","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Alert | CLOVER BIO-B (02197) Surges Over 21% Following Announcement of Phase I Clinical Trial Launch for Respiratory Combination Vaccine Candidates","media":"Stock News","content":"<p>CLOVER BIO-B (02197) surged over 21%, rising 21.15% to HK$2.75 with trading volume of HK$42.2186 million at the time of reporting. On the news front, in June this year, Clover Biopharmaceuticals announced that its respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) (Pre-F trimeric subunit vaccine antigens), developed based on the company's proprietary Trimer-Tag (protein trimerization) vaccine development platform, have completed enrollment of the first batch of subjects and officially launched Phase I clinical trials. Clover Biopharmaceuticals' Chief Executive Officer and Executive Director Liang Guo previously pointed out that while currently approved recombinant protein RSV vaccines are safe and effective, there remain key unmet clinical needs globally—including the inability to prevent and reduce the respiratory disease burden caused by viruses with similar RSV structures such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | CLOVER BIO-B (02197) Surges Over 21% Following Announcement of Phase I Clinical Trial Launch for Respiratory Combination Vaccine Candidates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | CLOVER BIO-B (02197) Surges Over 21% Following Announcement of Phase I Clinical Trial Launch for Respiratory Combination Vaccine Candidates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-02 11:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOVER BIO-B (02197) surged over 21%, rising 21.15% to HK$2.75 with trading volume of HK$42.2186 million at the time of reporting. On the news front, in June this year, Clover Biopharmaceuticals announced that its respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) (Pre-F trimeric subunit vaccine antigens), developed based on the company's proprietary Trimer-Tag (protein trimerization) vaccine development platform, have completed enrollment of the first batch of subjects and officially launched Phase I clinical trials. Clover Biopharmaceuticals' Chief Executive Officer and Executive Director Liang Guo previously pointed out that while currently approved recombinant protein RSV vaccines are safe and effective, there remain key unmet clinical needs globally—including the inability to prevent and reduce the respiratory disease burden caused by viruses with similar RSV structures such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4614","symbol_name":"Manus概念股","start_time":0,"source_url":"","article_id":"1163204562","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163204562","pubTimestamp":1759376209,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOVER BIO-B (02197) surged over 21%, rising 21.15% to HK$2.75 with trading volume of HK$42.2186 million at the time of reporting. On the news front, in June this year, Clover Biopharmaceuticals...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4614":"Manus概念股","HSCEI":"国企指数","02197":"三叶草生物-B","BK1161":"生物科技","07226":"南方两倍做多恒科","YANG":"三倍做空富时中国ETF-Direxion"},"translate_title":"港股快讯|三叶草生物-B(02197)宣布启动呼吸道组合候选疫苗I期临床试验后大涨超21%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YANG":1,"07226":1,"02197":1,"HSCEI":1},"content_text":"CLOVER BIO-B (02197) surged over 21%, rising 21.15% to HK$2.75 with trading volume of HK$42.2186 million at the time of reporting. On the news front, in June this year, Clover Biopharmaceuticals announced that its respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) (Pre-F trimeric subunit vaccine antigens), developed based on the company's proprietary Trimer-Tag (protein trimerization) vaccine development platform, have completed enrollment of the first batch of subjects and officially launched Phase I clinical trials. Clover Biopharmaceuticals' Chief Executive Officer and Executive Director Liang Guo previously pointed out that while currently approved recombinant protein RSV vaccines are safe and effective, there remain key unmet clinical needs globally—including the inability to prevent and reduce the respiratory disease burden caused by viruses with similar RSV structures such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163204562","isCrawlerRequest":true}